From Wikipedia, the free encyclopedia
Chemical compound
Stearoylethanolamide
|
Names
|
IUPAC name
N-(2-Hydroxyethyl)octadecanamide
|
Identifiers
|
|
|
|
|
ChemSpider
|
|
ECHA InfoCard
|
100.003.531
|
|
|
|
|
UNII
|
|
|
|
InChI=1S/C20H41NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h22H,2-19H2,1H3,(H,21,23) Key: OTGQIQQTPXJQRG-UHFFFAOYSA-N
|
CCCCCCCCCCCCCCCCCC(=O)NCCO
|
Properties
|
|
C20H41NO2
|
Molar mass
|
327.553 g·mol−1
|
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Chemical compound
Stearoylethanolamide (SEA) is an
endocannabinoid
neurotransmitter.
[1]
Stearoylethanolamide (
C20
H41
NO2; 18:0), also called N-(octadecanoyl)ethanolamine, is an
N-acylethanolamine and the
ethanolamide of
octadecanoic acid (C18H36
O2; 18:0) and
ethanolamine (MEA: C2H7NO), and functionally related to an octadecanoic acid.
[2]
Levels of SEA correlate with changes in pain intensity, indicating this SEA change, reflect the pain reduction effects of IPRP.
[3]
References
-
^ Mauro Maccarrone, Riccardo Pauselli, Marianna Di Rienzo, Alessandro Finazzi-Agrò (2002).
"Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells". Biochem J. 366 (Pt 1): 137–144.
doi:
10.1042/BJ20020438.
PMC
1222758.
PMID
12010121.
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
-
^ PubChem.
"N-(2-Hydroxyethyl)octadecanamide". pubchem.ncbi.nlm.nih.gov. Retrieved 2022-09-27.
-
^ Stensson, Niclas; Gerdle, Björn; Rönne-Petersén, Linn; Yang, Liu L.; Lavebratt, Catharina; Falkenberg, Torkel; Ghafouri, Bijar (2022-02-26).
"Investigating the Long-Term Effect of an Interdisciplinary Multimodal Rehabilitation Program on Levels of Bioactive Lipids and Telomerase Activity in Blood from Patients with Chronic Pain". Journal of Clinical Medicine. 11 (5): 1291.
doi:
10.3390/jcm11051291.
ISSN
2077-0383.
PMC
8911430.
PMID
35268382.
|
---|
Receptor (
ligands) |
CB1Tooltip Cannabinoid receptor type 1 | Agonists (abridged,
full list) | |
---|
Inverse agonists | |
---|
Antagonists | |
---|
|
---|
CB2Tooltip Cannabinoid receptor type 2 | Agonists |
-
2-AG
-
2-AGE (noladin ether)
-
3,3'-Diindolylmethane
-
4-O-Methylhonokiol
-
α-Amyrin · β-Amyrin
-
A-796,260
-
A-834,735
-
A-836,339
-
AM-1172
-
AM-1221
-
AM-1235
-
AM-1241
-
AM-2232
-
Anandamide
-
AZ-11713908
-
Cannabinol
-
Caryophyllene
-
CB-13
-
CBS-0550
-
CP 55,940
-
GW-405,833 (L-768,242)
-
GW-842,166X
-
HU-308
-
JTE 7-31
-
JWH-007
-
JWH-015
-
JWH-018
-
JWH-73
-
JWH-133
-
L-759,633
-
L-759,656
-
Lenabasum (anabasum)
-
Magnolol
-
MDA-19
-
Nabitan
-
NADA
-
Olorinab (APD-371)
-
PF-03550096
-
S-444,823
-
SER-601
-
Serinolamide A
-
UR-144
-
Tedalinab
-
THC (dronabinol)
-
THCV
-
Tetrahydromagnolol
-
Virodhamine
|
---|
Antagonists | |
---|
|
---|
NAGly (
GPR18) | |
---|
GPR55 | |
---|
GPR119 | |
---|
|
---|
Transporter (
modulators) |
eCBTsTooltip Endocannabinoid transporter | |
---|
|
---|
Enzyme (
modulators) | |
---|
Others |
- Others:
2-PG (directly potentiates activity of 2-AG at CB1 receptor)
-
ARN-272 (FAAH-like anandamide transporter inhibitor)
|
---|
|